MIRA
INFORM REPORT
|
Report Date : |
18.07.2007 |
IDENTIFICATION DETAILS
|
Name : |
LG LIFE SCIENCES CO., LTD. |
|
|
|
|
Registered Office : |
LG Twin Tower, 20, Yeouido-dong, Yeongdeungpo-gu, |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as on) : |
31.03.2007 |
|
|
|
|
Date of Incorporation : |
08/02/2002 |
|
|
|
|
Legal Form : |
Listed Company |
|
|
|
|
Line of Business : |
Manufacture of Biological Products |
RATING & COMMENTS
|
MIRA’s Rating : |
A |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
Status : |
Good |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
Basic
|
Company
Name |
LG LIFE SCIENCES CO., LTD. |
|
Registered Address |
20, Yeouido-dong, Yeongdeungpo-gu, |
|
Building |
LG |
|
Zip Code |
150-721 |
|
Tel |
+82-2-3773-5114 |
|
Fax |
+82-2-3773-7012 |
|
E-mail |
webmaster@lgls.co.kr |
|
Website |
www.lgls.co.kr |
|
Trading Address |
LG Twin Tower, 20, Yeouido-dong,
Yeongdeungpo-gu, |
|
Tel |
+82-2-3773-5114 |
|
Fax |
+82-2-3773-7012 |
|
Technology Institute |
104-1, Munji-dong, Yuseong-gu, |
|
Tel |
+82-42-866-2114 |
|
Fax |
+82-42-862-0332 |
|
Onsan Factory |
580, Hwasan-ri, Onsan-eup, Ulju-gun, |
|
Tel |
+82-52-231-5324 |
|
Fax |
+82-52-231-5328 |
|
Iksan Factory |
601, Yongje-dong, Iksan-si, |
|
Tel |
+82-63-830-4777 |
|
Fax |
+82-63-830-4204 |
|
Type |
Export |
|
Industry |
Manufacture of Biological Products |
|
Main Business |
Hepatitis-B Vaccine, Gemifloxacin, Human Growth Hormone, Supplementary
Agents, High-Blood Pressure Medicines, General Anemia Medicines, Acyesis
Treatments, Myalgia Treatments, Hepatitis Diagnostics |
|
Established (mm/dd/yyyy) |
08/02/2002 |
The Subject owns the premises of Onsan Factory and Iksan Factory.
Detailed Products
|
Activity |
Detailed Products (UNSPSC) |
|
Sell |
Hepatitis B virus vaccine(51201607) |
|
Sell |
Herbicides(10171700) |
|
Sell |
Antineoplastic agents(51110000) |
|
Sell |
Influenza virus vaccine(51201608) |
|
Sell |
Veterinary nutritional supplement(51250000) |
|
Sell |
Antihypertensive drugs(51121700) |
|
Sell |
Dietary supplements and nutritional therapy
products(51191900) |
|
Sell |
Veterinary antibiotics(51102600) |
|
Sell |
Immunology analyzer accessories or
supplies(41115820) |
|
Sell |
Antihypertensive drugs(51121700) |
|
Sell |
Nonsteroidal anti inflammatory drugs
NSAIDs(51142100) |
|
Sell |
Growth hormones and their
inhibitors(51182300) |
|
Sell |
Calcium salts and calcium
regulators(51182400) |
|
Sell |
Thrombolytic drugs and platelet aggregation
inhibitors(51131700) |
|
Sell |
Gonadotropic hormones and ovarian stimulants
and inhibitors(51181900) |
|
Sell |
Livestock feed(10121500) |
|
Sell |
Metabolites(51251000) |
|
Sell |
Centrally acting skeletal muscle
relaxants(51151900) |
CEO’s
|
Name |
Kim In-Chull |
|
Date of Birth |
07/07/1951 |
|
Title |
President & CEO |
|
Sex |
Male |
|
Nationality |
Korean |
-Education
02/1977 Master's
degree from
09/1985 Ph.D. in
Physical Science from
-Career
06/1985
Post-doctorate work at Rockefeller Foundation
06/1986 Researcher
at
11/1988 Head
researcher at Glaxo
01/1993 General
Manager at Lucky
03/1995 Vice
President at LG Chemical
04/2001 Head of the
Pharmaceutical Development Lab at LGCI
10/2002 Head of
Business development at LG Life Sciences
01/2005 Exec. Vice
President and Chief of Sales Division at LGLS
01/2006 CEO of LGLS
-Award
09/2000 The Grand
prix for the 9th Dasan Technology Award
Profiles
|
Capital |
84,066,030,000 KRW |
|||||||||||||||||||||
|
Employees |
1,089 |
|||||||||||||||||||||
|
Formation |
Listed Company ( A Company of LG Business Group |
|||||||||||||||||||||
|
Bank Details |
|
|||||||||||||||||||||
|
Corporate Registered No. |
110111-2581183 |
|||||||||||||||||||||
|
Business Registered No. |
107-86-21066 |
|||||||||||||||||||||
|
Permit & Licenses |
N/A |
|||||||||||||||||||||
|
Shareholder Position |
|
Company History
08/2002 LG Life Sciences launched (after
being spun off from LGCI); Executive Vice President Yang Heung-joon named CEO.
10/2002 Request submitted to FDA for Phase
II Clinical Trial of LB80380, a hepatitis B treatment; marketing agreement for
Thymitaq hepatitis treatment signed with Eximas of the US; American and
European sales agreement for FACTIVE® signed with Genesoft (US).
11/2002 Korean genes for discovered for
liver, stomach and pancreatic cancers.
12/2002 Patents for production technology
related to sustained release human growth hormone perceived from 22 European
countries; permission received to put FACTIVE® tablets on the Korean market.
03/2003 Second phase of construction
completed at Iksan pharmaceutical plant.
04/2003 FACTIVE® quinolone antibiotics
approved by US FDA.
08/2003 FACTIVE® given IR52 Chang Young-sil
Award.
09/2003 Permission to use KT Mark with
FACTIVE®
02/2004 FACTIVE® given IR52 Chang Young-sil
Award of the Year for 2003 (Presidential Prize).
03/2004 FACTIVE® approved as a new drug in
04/2004 Technology for hepatitis B treatment
exported to Anadys Pharmaceuticals of the
05/2004 Environmentally-safe herbicide
(flucetosulfuron) commercialized.
06/2004 Request submitted for first registration
of bio-generic drugs in
08/2004 DepoMed of the
09/2004 Sales of FACTIVE® begun in US.
11/2004 Biogen Idec of the
04/2005 Joint research begun with the Korea
Research Institute of Bioscience and Biotechnology on protein chips, the
next-generation in diagnostics.
05/2005 Comprehensive cooperative research
agreement signed with
07/2005 Nov. 2004: Kyorin Pharmaceutical Co.
of Japan grants exclusive license to sell its urinary incontinence treatment in
08/2005 Development of
08/2005 Joint research of dementia treatment
begun with the
09/2005 Degenerative arthritis treatment
(HYRUAN Plus™) commercialized.
09/2005 Phase II Clinical Trial for
sustained release human growth hormone given to young children begun in
09/2005 Technology for FACTIVE® quinolone
antibiotics exported to aRigen Inc. of Japan.
01/2006 Executive President In-chel Kim
named CEO
02/2006 Joint marketing agreement for XILEP
XL® hyperlipidemia treatment concluded with Korea Novartis.
04/2006 European marketing approval of human
growth hormone of Valtropin™.
05/2006 Launch of Novamet GR for treatment
of diabetes.
07/2006 Development and commercialization of
Follitrope™, an ovulation induction treatment.
09/2006 Co-marketing partnership with
Novartis
10/2006 Development of DPP-4 class diabetes
treatment.
12/2006 LGLS receives 2006 Most Respected
Company Award.
01/2007 FDA approval of sustained
release-human growth hormone of Declage™.
01/2007 Development and commercialization of
chemoprotectant of Epitrol™.
(Before
Spin-off)
04-2001 Demerged into three separate
companies: LG Chem Investment, LG Chem and LG Household & Health Care.
Renamed LG Chem Investment, Ltd.
12-2000 Employs functional genomics for anti-cancer
research with Gene Logis Inc.
05-2000 Invests US$30 Million in Elitra
Pharmaceuticals for collaboration
03-2000 Establishment of ‘Bio-Fund’
01-2000 Releases a new, powerful pulmonary
hypertension treatment 'Zanidip®'
Dedication ceremony for pharmaceutical
(antibiotics) plant in Iksan
12-1999 Completes phase 3 trials on
flouroquinolone and submits application to FDA for the marketing of
flouroquinolone antibiotic
11-1999 Strategic alliance with Rhom &
Haas for marketing of herbicide ‘Pyanchor’
Completes registration of the insecticide
‘Permethrin’ with the US EPA, the first time in
10-1999 New fungicide ‘Guardian’ awards the
Central Patent Technology Prize
03-1999 Succeeds in developing the new
fungicide ‘Guardian’
02-1999 Collaboration with SmithKline
Beecham (now GSK) of
10-1998 Eutropin, selected by Daily Chosun
as one of the 50 best items during the 50th anniversary of the Nation’s Foundation
09-1998 Flouroquinolone successfully
completes phase 2 trials in the
06-1998 Quinolone Team of Life Science
Research Institute awards the Patent Technology Prize & the Admiral
Chungmu-gong Prize
05-1998 Herbicide ‘Pyanchor’, Arthritis
treatment ‘Hyaluron Acid’ acquires the KT mark and receives the LG R&D
Grand Prize
10-1997 Marketing alliance with Pasteur
Merieux Connaght for Euvax B™ Injection (recombinant hepatitis B vaccine)
Strategic alliance with Merck of Germany for
the marketing of bio-engineered pharmaceuticals
08-1997 Forms strategic alliance with Warner
Lambert of
06-1997 Exports hepatitis vaccine Euvax B™
to the
05-1997 Signs strategic alliance with
Smithkline-Beecham (now GSK) of
Commercialization of intermediate
cephalosporin antibiotic, ‘DAMA’
03-1997 Succeeds in the commercialization of
the new herbicide, ‘Pyanchor’
12-1996 Approves by World Health
Organization for the worldwide supply of Euvax B™ Injection
10-1995 Strategic alliance with TBC of U.S.
for the research and marketing of bio-technology products
04-1995 Commercialization of recombinant
human granulocyte macrophage-colony stimulating factor (Leucogen™)
Completes construction of Iksan
pharmaceutical plant
02-1995 Renames as of LG Chemical Ltd.,
Pharmaceutical Division (now LGCI Ltd., Pharmaceutical Division)
10-1994 Opens world class R&D center, ‘LG
Chemical Research Park’ (now Life Science Research Institute)
06-1994 Bio-engineered pharmaceuticals
(Eutropin™, Intermax alpha™, Euvax B™) make inroads into the South American
market
05-1994 Commercialization of 3rd generation
diagnostics for hepatitis C (HCD 3.0™) and its confirmatory diagnostics (HCD
Confirm™)
09-1993 Full-scale market launching of
Hepatitis vaccine injection (Euvax B™) in
02-1993 Commercialization of recombinant
human growth hormone (Eutropin™)
11-1992 Commercialization of recombinant
hepatitis B vaccine (Euvax B™)
10-1992 Exports Intermax gamma™, Intermax
alpha™ Injections and Hepatitis B vaccine to
09-1992 Develops genetically-engineered
human growth hormone (Eutropin™)
07-1992 Commercialization of interferon
alpha preparation (Intermax alpha™) for the treatment of cancer and hepatitis
02-1992 Exports US$4 Million of Intermax
gamma™ Injection to
First global market launching of
genetically-engineered pharmaceutical products
Commercialization of in-vitro diagnosis for
hepatitis C (Lucky HCD™)
11-1991 Merges into Lucky Ltd.
06-1991 Discovers the structure of Hepatitis
C virus (typical type for Korean)
Opens Lucky
01-1991 The first development of 4th
generation cephalosporin antibiotics in the world
Technology transfer to Glaxo-Wellcome of
09-1990 Commercialization of Interferon
gamma preparation (Intermax gamma™)
04-1990 Changes company name to Lucky
Pharmaceuticals
11-1989 Central Research Institute develops
lactation stimulant for cows 'BST®'
08-1989 Acquisition of Ah-Jin
Pharmaceuticals
06-1989 Develops gamma-interferon for the
first time in
06-1988 Develops running water-use
insecticide ‘Etopenprox’ as second in the world
08-1986 Develops 3 kinds of In-Vitro
Diagnostics for Hepatitis with genetic recombinant technology (Lucky HCD™)
02-1986 Completes construction of non-
pollutant agrochemical technical grade factory
1984 Opening of Lucky Biotech Corporation in
05-1984 Establishment of Pharmaceuticals
Division
1983 Initiation of research on biotechnology
12-1981 Establishes Genetic Engineering
Research Part in Central Research Institute
11-1979 Foundation of Lucky Central Research Institute in Daeduk,
The Subject Company
is a Korea-based company engaged in the provision of pharmaceutical products.
The Company operates its business through three divisions: pharmaceuticals,
agrochemicals and animal health. The Company's pharmaceutical products include
human growth hormones (Eutropin); leukocyte production stimulants (Leucogen);
interferons (Intermax Alpha and Intermax Gamma); vaccines; supplementary agents
for ophthalmologic operations (Hyal 2000), and remedies for high-blood
pressure, anemia, acyesis, myalgia and hepatitis. The Company also offers
pharmaceutical intermediates, including aminothiazole, cephalosporin,
nucleoside and anti-fungal intermediates. In addition, the Company produces
veterinary medicines such as bovine somatotropin, antibiotics and anthelmintics,
and agrochemicals including fungicides, herbicides and insecticides.
Headquartered in
Management
|
Job Description |
Title |
Name |
Sex |
Nationality |
Inauguration Day |
|
President & CEO |
Dr. |
Kim In-Chull |
Korean |
51.07.07 |
Illinois University-USA |
|
Director |
Mr. |
Kim Joo-Hyung |
Korean |
55.07.03 |
|
|
Director & CFO |
Mr. |
Yang Han-Young |
Korean |
49.09.04 |
|
|
Director |
Mr. |
Han Myung-Ho |
Korean |
59.07.07 |
|
|
Outside Director |
Mr. |
Choi Chang-Rak |
Korean |
40.02.11 |
|
|
Outside Director |
Mr. |
Shim Cvhang-Koo |
Korean |
48.07.21 |
|
|
Outside Director |
Mr. |
Kim Soon-Ki |
Korean |
53.01.26 |
Huston University-USA |
Financials
Unit: KRW
|
Year |
Sales |
Assets |
Net income |
|
221,204,651,923 |
389,359,069,138 |
5,930,494,927 |
|
|
2005 |
213,252,354,218 |
383,329,657,204 |
(-)923,963,402 |
|
2004 |
213,636,024,824 |
396,471,198,545 |
10,073,423,277 |
|
2003 |
179,037,402,211 |
340,667,437,918 |
3,011,089,070 |
Financial Description
Unit: KRW
|
Authorized Capital |
190,000,000,000 |
|
Paid-Up Capital |
84,066,030,000 |
|
Total Issues Shares |
16,813,206 |
|
Balance Sheet |
|||
|
Unit : Korean Won |
01/01/2007~03/31/2007 |
As of 12/31/2006 |
As of 12/31/2005 |
|
Total Assets |
393,730,001,934 |
389,359,069,138 |
383,329,657,204 |
|
Current Assets |
194,393,600,353 |
187,617,499,888 |
165,467,222,499 |
|
-Quick Assets |
156,715,275,373 |
154,055,290,167 |
136,151,638,857 |
|
-Inventories |
37,678,324,980 |
33,562,209,721 |
29,315,583,642 |
|
Fixed Assets |
199,336,401,581 |
201,741,569,250 |
217,862,434,705 |
|
-Investment |
1,803,753,295 |
1,762,813,781 |
6,304,494,953 |
|
-Tangibles |
97,811,043,209 |
100,633,610,871 |
110,892,440,466 |
|
-Intangibles |
91,748,569,751 |
91,519,583,676 |
87,360,357,335 |
|
-Others |
7,973,035,326 |
7,825,560,922 |
13,305,141,951 |
|
Total Liabilities |
148,792,644,059 |
146,535,879,652 |
144,172,105,213 |
|
Current Liabilities |
36,399,683,393 |
34,839,348,951 |
32,649,607,770 |
|
Fixed Liabilities |
112,392,960,666 |
111,696,530,701 |
111,522,497,443 |
|
Capital Stock |
84,066,030,000 |
84,066,030,000 |
84,066,030,000 |
|
Capital Surplus |
147,045,545,174 |
147,045,545,174 |
147,045,545,174 |
|
Profit Surplus |
14,817,021,058 |
12,761,284,703 |
6,830,789,776 |
|
Capital Adjustment |
(-)151,600 |
(-)151,600 |
(-)114,800 |
|
Total Equity |
244,937,357,875 |
242,823,189,486 |
239,157,551,991 |
|
Liab. & Shareholder’s Equity |
393,730,001,934 |
389,359,069,138 |
383,329,657,204 |
|
Current
Liabilities |
36,399,683,393 |
34,839,348,951 |
32,649,607,770 |
|
Trade Payables |
11,274,667,666 |
9,002,188,260 |
9,261,413,922 |
|
Account Payables |
13,232,670,217 |
11,800,587,303 |
13,154,369,331 |
|
Advance Receipts |
250,328,513 |
67,410,759 |
31,245,453 |
|
Unearned Income |
- |
- |
155,419,177 |
|
Withholdings |
5,554,864,488 |
8,346,664,972 |
8,102,717,734 |
|
Accrued Expenses |
1,590,628,530 |
944,444,444 |
946,474,531 |
|
Accrued Income Tax |
3,386,470,212 |
3,471,957,212 |
- |
|
Current Portion of Long-Term Debts |
- |
- |
105,155,505 |
|
Provision for Refund |
275,472,115 |
278,044,702 |
294,834,684 |
|
Non-Current Portion of Deferred Income Tax
Credit |
834,581,652 |
928,051,299 |
597,977,433 |
|
Fixed
Liabilities |
112,392,960,666 |
111,696,530,701 |
111,522,497,443 |
|
Debentures |
100,000,000,000 |
100,000,000,000 |
100,000,000,000 |
|
Long-Term Account Payables |
2,244,496,000 |
2,168,140,000 |
- |
|
Guarantee Deposit Withholds |
5,000,000 |
5,000,000 |
5,000,000 |
|
Provision for Severance & Retirement |
16,499,135,949 |
16,177,076,010 |
17,793,605,399 |
|
Non-Current Portion of Deferred Income Tax
Credit |
3,196,324,072 |
3,716,635,474 |
5,557,933,301 |
|
Income Statement |
|||
|
Unit : Korean Won |
01/01/2007~03/31/2007 |
As of 12/31/2006 |
As of 12/31/2005 |
|
Sales |
57,464,505,728 |
221,204,651,923 |
213,252,354,218 |
|
Cost of Sold Goods |
27,425,259,473 |
101,201,745,881 |
98,563,893,193 |
|
Gross Profit |
30,039,246,255 |
120,002,906,042 |
114,688,461,025 |
|
Selling & Admin. Expenses |
27,561,627,108 |
111,202,215,200 |
114,273,566,515 |
|
Operating Income |
2,477,619,147 |
8,800,690,842 |
414,894,510 |
|
Non-Operating Income |
3,340,976,865 |
11,474,394,446 |
10,597,362,416 |
|
Non-Operating expenses |
2,783,112,815 |
11,070,371,707 |
16,400,056,036 |
|
Ordinary Income |
3,035,483,197 |
9,204,713,581 |
(-)5,387,799,110 |
|
Special Income |
- |
- |
- |
|
Income Before Taxes |
3,035,483,197 |
9,204,713,581 |
(-)5,387,799,110 |
|
Income Taxes Expenses |
979,746,842 |
3,274,218,654 |
(-)4,463,835,708 |
|
Net Income |
2,055,736,355 |
5,930,494,927 |
(-)923,963,402 |
|
Cash Flows |
|||
|
Unit : Korean Won |
01/01/2007~03/31/2007 |
As of 12/31/2006 |
As of 12/31/2005 |
|
Cash Flows from Operating |
3,054,096,307 |
20,018,621,720 |
6,699,623,413 |
|
-Net Income |
2,055,736,355 |
5,930,494,927 |
(-)923,963,402 |
|
-Exp. without Cash Outflow |
9,327,886,658 |
32,633,248,730 |
35,734,644,833 |
|
-Revenue without Cash Inflows |
(-)708,418,695 |
(-)2,565,179,473 |
(-)2,448,056,984 |
|
-Changes in Asset/ & Liability |
(-)7,621,108,011 |
(-)15,979,942,464 |
(-)25,663,001,034 |
|
Cash Flows from Investing |
1,138,659,321 |
(-)20,854,040,296 |
(-)1,281,901,664 |
|
-Cash Inflow from Investing |
10,916,183,873 |
36,653,885,781 |
59,777,390,749 |
|
-Cash Outflows for Investing |
(-)9,777,524,552 |
(-)57,507,926,077 |
(-)61,059,292,413 |
|
Cash Flows from Financing |
- |
(-)105,192,305 |
(-)1,729,427,160 |
|
-Cash Inflows from Financing |
- |
- |
98,522,276,000 |
|
-Cash Outflows from Financing |
- |
(-)105,192,305 |
(-)100,251,703,160 |
|
Increase/Decrease in Cash |
4,192,755,628 |
(-)940,610,881 |
3,688,294,589 |
|
Cash at the Beginning of Year |
18,894,770,060 |
19,835,380,941 |
16,147,086,352 |
|
Cash at the End of Year |
23,087,525,688 |
18,894,770,060 |
19,835,380,941 |
Products,
Technologies, Services
Description
|
Main Products & Services |
Pharmaceuticals, Animal Health, Pharmaceutical
Intermediates, Agrochemicals |
|
Detailed Products Spec. |
1.
Pharmaceuticals:
Vaccines, Recombinant, Biological Products, Sodium Hyaluronate, Infertility
Treatment, Antibiotics, Anti-Cancer Drugs, Anti-Viral Drugs, In-Vitro
Diagnostics, Raw Materials, Antibiotics 2.
Animal Health:
Genetic Engineering Product, Antibiotics, Anthelmintic, Feed Additive 3.
Pharmaceutical
Intermediates: Aminothiazole, Cephalosporin Products (Crude), Nucleoside, Intermediate
for Anti-Fungal, Intermediate for Cilostazole, Intermediate for radiopaque
contrast media 4.
Agrochemicals:
Fungicide, Herbicide, Insecticide |
|
Technologies Acquired |
An antibiotic / the formal approval from
the U.S. Federal Drug Administration |
Trade Partners
|
Suppliers |
Recordati Techwell Fukang Yangnong |
|
Customers |
The Subject supplies its products to
Hospitals and farmers. |
|
Competitors |
Syngenta Bayer Monsanto Dow Dupont |
Related Parties (Subsidiaries,
Joint-
Venture &
Affiliates)
|
Overseas Office |
Beijing Representative Office Room TEL:+86-10-8458-3052/3 FAX:+86-10-8458-3055 LG International Do Av. Dr., Chucri, Zaidan, 940, 3o andar
Market Place (Tower II), Sao Paulo CEP 04583-110, SP, Brazil TEL:+55-11-2162-5610 FAX:+55-11-2162-5613 |
|
Subsidiary |
LG LIFE SCIENCES LG House, AB-3, Commercial Complex,
Safdarjung Enclave, New Delhi-110 029, TEL:+91-11-2671-4004 FAX:+91-11-2671-3716 LG LIFE SCIENCES POLAND SP.Z.O.O (100% held
by the subject company) ul. Grzybowska 80/82 00-844 TEL:+48-22-661-55-15 FAX:+48-22-651-55-13 LG BIOMEDICAL, INC (100% held by the
subject company) |
|
Cooperative |
Takeda-Japan Oscient Pharmaceuticals Corp.- Anadys Pharmaceuticals, Inc.- |
Affiliates
LG ELECTRONICS INC.
26th Fl., LG Twin Tower West Annex, 20,
Yeouido-dong, Yeongdeungpo-gu,
LG Micron Ltd.
Address: LG Micron, 624, Gupo-dong, Gumi-si,
Gyeongbuk-do 730-713
Tel: 82-54-475-3800 Fax: 82-54-479-0360
Industry: Manufacture of Other Electronic
Valves, Tubes and Electronic Components n.e.c.
LG. Philips LCD Co., Ltd.
Address: 17Fl. LG Twin Tower West, 20
Youido-dong, Yongdungpo-gu,
Tel: 82-2-3777-1010 Fax: 82-2-3777-0795
Industry: Manufacture of liquid crystal
displays
LG Chem, Ltd.
Address: 17 LG Twin Tower East 20
Youido-dong, Yongdungpo-gu,
Tel: 82-2-3773-5114 Fax: 82-2-3773-7933
Industry: Manufacture of Basic Organic
Petrochemicals
LG Telecom Co., Ltd.( 110111-1296676)
Address: 20F LG Gangnam Tower 679 Yeoksam
1-dong Gangnam-gu,
Tel: 82-2-2005-7114 Fax: 82-2-2005-7337
Industry: Mobile Telephone Services
LG INNOTEK CO., LTD. (110111-0192180)
Address: 33th Fl., LG Twin Tower West Annex, 20,
Yeoeuido-dong, Yeongdeungpo-gu,
Tel: 82-2-3777-1114 Fax: 82-2-3777-0082
Industry: Manufacture of Communication Apparatuses
Without Any Line Connection and Radio or Television Broadcasting Apparatuses
LG Dacom Corporation(110111-0315948
Address: Dacom Bldg., 706-1, Yeoksam 2-dong,
Gangnam-gu,
Tel: 82-1544-0001 Fax: 82-2-6220-1929
Industry: Leased Line Services
LG Household ＆ Health Care
Ltd.
Address: LG Twin Tower, 20 Youido-dong,
Yongdungpo-gu,
Tel: 82-2-3773-1114 Fax: 82-2-3773-7032
Industry: Manufacture of Toothpaste, Soap and
Synthetic Detergents
LG Petrochem. Co., Ltd.
Address: 21th Fl., Twin Tower East, 20
Youido-dong, Yongdungpo-gu,
Tel: 82-2-3773-3829 Fax: 82-2-3773-3929
Industry: Wholesale of Non-Specialized Goods
LG INTERNATIONAL CORPORATION
Address: 12th Fl., LG Twin Tower East Annex, 20,
Yeouido-dong, Yeongdeungpo-gu,
Tel: 82-2-3773-5114 Fax: 82-2-3773-5273
Industry: Manufacture of Biological Products
SERVEONE(110111-2411520)
LG Management Development Institute
(110111-0423494)
LG CNS Co., Ltd. (110111-0516695)
LG NOTEL
(LG Innotek Huizhou
Co.,Ltd)
(SERVEONE(
Arcelic-LG Klima
Sanayi Ve Ticarte A.S(LGEAT)
Beijing LG
Household Chemical Co., Ltd.
Compact Power Inc.
DACOM America Inc.
De Zwarte Ponk
B.V.(DZP)
Eic Properties
Pte.Ltd.
Electromagnetica
Goldstar S.R.L
EPC Munai LLP
FOSCO B.V.
GFTZ LG
International Ltd.
Goldstar
Electronics Thailand Co.,Ltd.
Hangzhou LG
Cosmetics Co., Ltd.
Hi Logistics
Hi Logistics
Intec LG CNS, INC
Lanchao
LG(Yantai)Digital
Langchao LG Digital
LG (
LG (Yantai)
Information & Communication Tech.
LG Alina Electonics(LGERI)
LG Biomedical
Institute
LG CHEM BRASIL
INTERMEDICAO DE NEGOCIOS DO SETOR QUIMICO LTDA.
LG Chem Display
Material Co., Ltd
LG Chem
LG Chem
LG Chem Industrial
Materials Inc.
LG Chem
LG Chem Taiwan, Ltd.
LG Chem(
LG Chem(
LG Chem(
LG Chemical America
Inc.
LG Chemical Hong
Kong Ltd.
LG Chemical India
Private Ltd.
LG Chemical Trading
co., LTD
LG Chemical(
LG CNS America, Inc
LG CNS Brasil
Servicos De T.I.LTDA
LG CNS China, Inc
LG CNS Europe B.V
LG CNS Global
Private Limited
LG CNS Malaysia SDN
BHD
LG CNS Philipines,
Inc
LG Elctronics
Norway AS
LG Electonics Huizhou
Ltd.
LG Electronics
(Kunshan) Computer Co., Ltd.
LG Electronics (
LG Electronics (
LG Electronics
LG Electronics
Alabama, Inc. (LGEAI)
LG Electronics
Almaty Kazak Co., Ltd.(LGEAK)
LG Electronics
LG Electronics
Argentina S.A.(LGEAR)
LG Electronics
LG Electronics
LG Electronics
LG Electronics
Canada,Inc. (LGECI)
LG Electronics
China Co., Ltd. (LGECH)
LG Electronics
LG Electronics
Czech s.r.o.
LG Electronics Da
Amazonia Ltda (LGEAZ)
LG Electronics De
Sao Paulo Ltda. (LGESP)
LG Electronics
Deutschland.Gmbh. (LGEDG)
LG Electronics
LG Electronics
LG Electronics
Espana S.A. (LGEES)
LG Electronics
European Holdings B.V.
LG Electronics
European Logistics & Services B.V.
LG Electronics
European Shared Service Center B.V.
LG Electronics
LG Electronics Gulf
FZE (LGEGF)
LG Electronics
LG Electronics HK
Ltd.(LGEHK)
LG Electronics Inc.
LG Electronics
LG Electronics
LG Electronics
Japan Inc. (LGEJP)
LG Electronics JIT
LG Electronics
LG Electronics
Magyar KFT. (LGEMK)
LG Electronics
LG Electronics
Mexicali, S. A. de C. V. (LGEMX)
LG Electronics
Mexico S.A. de C.V (LGEMS)
LG Electronics
Middle East Co., Ltd.
LG Electronics
Mlawa Sp.zo.o (LGEMA)
LG Electronics Mobile
Research
LG Electronics
Mobilecomm
LG Electronics
Moblecomm
LG Electronics
Monterrey Mexico S.A. de C.V.
LG Electronics
LG Electronics
Nanjing Display Co.,Ltd
LG Electronics Nature(
LG Electronics
Nigeria Limited(LGENI)
LG Electronics
Nordic AB
LG Electronics
Overseas Trading FZE
LG Electronics
Panama S.A. (LGEPS)
LG Electronics Peru
S.A. (LGEPR)
LG Electronics
Philippines, Inc. (LGEPH)
LG Electronics
Polska SP.ZO.O (LGEPL)
LG Electronics
Portugal S.A.
LG Electronics
Qinhuangdao Co.,Ltd(LGEQH)
LG Electronics
Raynosa, S.A.de C.V(LGERS)
LG Electronics
LG Electronics
RUS.LLC
LG Electronics
RUS-Marketing, LLC
LG Electronics S.A.(PTY)
Ltd. (LGESA)
LG Electronics
Singapore Pte Ltd
LG Electronics
Taiwan Taipei Co., Ltd.
LG Electronics
Thailand Co.,Ltd.(LGETH)
LG Electronics
Tianjin Appliances Co., Ltd.
LG Electronics
Uklaine
LG Electronics
United Kingdom Ltd. (LGEUK)
LG Electronics USA
Inc. (LGEUS)
LG Electronics
Vietnam Ltd. (LGESV)
LG Electronics
Wales Ltd. (LGEWA)
LG Electronics
LG Electronics(
LG H&H Trading(
LG Holdings Ltd.
(LGHK)
LG Household &
Health Care America, Inc
LG Innotek Mexicali
S.A. De C.V
LG Innotek Poland
Sp. zo.o.
LG Innotek USA Inc.
LG Innotek Yantai
Co., Ltd
LG International
America Inc.
LG International
Corp.(
LG International
Japan Ltd.
LG International(
LG
International(Deutchland) Gmbh
LG
International(HK) Limited
LG International(
LG Life Sciences
India Pvt,Ltd
LG Life Sciences
Poland, Ltd
LG Micron(
LG Micron(
LG Mitr Electronics
Co., Ltd. (LGEMT)
LG Philips LCD
America Inc.
LG Philips LCD
Germany Gmbh
LG Philips LCD
Hongkong Co.,Ltd
LG Philips LCD
Japan Co.Ltd.
LG Philips LCD
Nanjing Co. Ltd
LG Philips LCD
Taiwan Co. Ltd. (LGPLT)
LG Properties Pte.
Ltd.
LG Soft India PVT
Ltd.(LGSI)
LG Solid Source,
LLC
LG Vina Chemical
J/V Company
LG VINA Cosmetics
LG.Philips LCD
Poland Sp. Z o.o.
LG.Philips LCD
Shanghai Co., Ltd.
LG-Shaker
Co.,Ltd(LGESR)
LG.Philips LCD
Guangzhou Co., Ltd.
Nakhodka
NanJing LG Panda
Appliances Co., Ltd. (LGEPN)
Ningbo LG Yongxing
Chemical Co., Ltd.
Ningbo LG Yongxing
Latex Co., Ltd.
Philco Resources
Limited
PT LG CNS Indonesia
PT LG Electronics
PT. LG Innotek
Qingdao LG Lanchao
Digital Communication Co., Ltd.
Shanghai LG
Electronics Co., Ltd. (LGESH)
Siltron America,
Inc.
Taizhou LG
Electronic Refrigeration Co.Ltd(LGETR)
Tianjin LG
Window & Door Co. Ltd.
Tianjin LG Bohai
Chemicl Co.,Ltd.
Tianjin LG Dagu
Chemical Co., Ltd.
TKNK Investments
B.V(Tatarstan
Triveni Digital
Inc.
Zenith Electronics
Co. (Zenith)
Sales by Region (Activity
& Markets)
|
Sales/ Unit :Mil KRW |
2006 |
2005 |
2004 |
|
Export |
76,400 |
79,696 |
88,301 |
|
Domestic |
140,179 |
123,788 |
103,814 |
|
Others |
4,626 |
9,768 |
21,521 |
|
Total |
221,205 |
213,252 |
213,636 |
Court Action
No.
News Clipping
R&D Spending by Korean Companies Slow Down in 2006
MAEIL NEWSPAPER 04/16/2007
Korean companies spent 14.5 trillion won on research and development
(R&D) last year, which is up 3.08 percent from previous year.
Total spending made by 531 listed firms in the domestic securities
market excluding financial companies and holding companies have amounted to
14.52 trillion won in 2006, the Korea Exchange said on April 16.
However, their spending growth on R&D sector has slowed down to 3
percent range, much lower than 10.68 percent in 2005.
Furthermore, the R&D ratio to sales fell to 2.3 percent, down 0.07
percentage points from the previous year.
The figure of 2.3 percent means that domestic listed companies spent 23
won on average on R&D when they sold 1,000 won worth of products.
Meanwhile, listed firms in the top ten list (in terms of market value)
-- including Samsung Electronics, POSCO, Korea Electric Power Corporation,
Hyundai Heavy Industries, SK Telecom, Hynix, Hyundai Motor, LG.Philips LCD, KT
and SK -accounted for 60.28 percent of the whole amount of R&D expenses
spent by listed companies. Overall spending made by the top 10 companies
reached 8.75 trillion won.
The top ten companies accounted for 59.58 percent in 2004 to 59.60
percent in 2005 and 60.28 percent in 2006, respectively, in terms of the
R&D spending.
Particularly, Samsung Electronics topped the list as it invested 5.57
trillion won in R&D, which accounted for 38.39 percent of the total R&D
expenditure, followed by Hyundai Motor (1.04 trillion won) and LG Electronics
(981 billion won).
Companies which recorded a relatively large amount of R&D expenses
as a percentage of the firm's sales were NCsoft (32.59 percent), LG Life
Sciences (27.56 percent), Mirae Corporation (16.08 percent), RNL BIO (12.78
percent) and Samsung Electro-mechanics (12.10 percent).
[
Domestic Gene Therapy Receives
MAEIL NEWSPAPER:11/06/2006
* Domestic Gene Therapy Receives U.S. FDA Clinical Trial Approval
ViroMed, a Korean gene and cell-based medicine development corporation,
disclosed on Monday that its self-developed gene therapy (VM202) was approved
to receive a phase 1 clinical trial from America's FDA (Food and Drug
Administration).
This is the first time that a domestically-developed biopharmaceutical
was approved for clinical tests from the U.S. FDA.
LG Life Sciences' "Factive," which had received sales
approval, is a chemically synthesized drug.
Clinical tests are usually conducted from phase one to three, where
phase 1 aims to monitor the appropriate dosage of the medicine, toxic issues and
drug's process in the body.
In phase 2, the phase 1-decided drug dosage will be confirmed as well as
the medicine's effect.
In phase 3, the tests are expanded to the human body while the product
is out in the market along with clinical tests.
According to ViroMed, the clinical trial is to be conducted at
The phase 1 clinical trial is expected to last approximately three to
four months.
[Dong-eun Lee / CJB]
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems comparatively
below average/normal. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)